免疫治疗联合放疗在宫颈癌与子宫癌中的临床试验现状
本综述汇总了免疫治疗联合放疗在宫颈癌和子宫癌中的临床试验进展。早期试验显示联合治疗疗效可观且毒性可耐受,目前正在探索局部晚期宫颈癌超越标准放化疗的优化方案,以及基于分子分型的子宫癌免疫调节策略。
要点
- 免疫治疗联合放疗在实体瘤中显示协同作用,早期试验疗效可观且毒性可耐受。
- 局部晚期宫颈癌正探索超越三十年标准放化疗的免疫联合方案。
- 子宫内膜癌中POLE突变和MSI-H亚型具免疫原性,正探索免疫联合策略。
核心结论
- 免疫治疗联合放疗在宫颈癌和子宫癌中正通过多项临床试验积极探索,早期结果提示疗效可观且毒性总体可耐受。
研究设计与样本
- 本篇为综述,汇总正在进行的免疫治疗联合放疗治疗宫颈癌和子宫癌的临床试验。
主要发现
- 放疗可诱导树突状细胞迁移、T细胞活化与增殖,并增加肿瘤浸润淋巴细胞。
- 免疫检查点阻断联合放疗的免疫调节效应正在辅助、根治和转移场景中积极研究。
- 早期试验显示联合治疗模式疗效可观且毒性总体可耐受。
- 宫颈癌多在高危型HPV持续感染后发生,病毒癌蛋白导致细胞改变和永生化并可能形成免疫耐受。
- 子宫癌按驱动突变、突变负荷和拷贝数改变分为4个分子亚类,其中POLE突变和MSI-H亚型可能占子宫内膜癌达40%且具免疫原性。
临床怎么用
- 局部晚期宫颈癌可关注超越标准放化疗的免疫联合放疗临床试验。
- 子宫内膜癌可依据分子分型(POLE突变、MSI-H)考虑免疫调节联合策略的临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Novel therapies combined with radiation continue to be of significant interest in the developmental treatment paradigm of gynecologic cancers. Clinical implementation of immunotherapy in oncology has rapidly changed the treatment landscape, options, paradigm, and outcomes through clinical trials. Immunotherapy has emerged as a therapeutic pillar in the treatment of solid tumors with demonstrable synergistic activity when combined with radiation therapy and chemoradiotherapy by an alteration or enhancement of the immune system. In solid tumors, radiation therapy induces migration of dendritic cells, T cell activation, and proliferation, and increases in tumor-infiltrating lymphocytes. These immunomodulatory effects in conjunction with immune checkpoint blockade are currently under active investigation in the adjuvant, definitive, and metastatic settings. Results from early phase trials demonstrate promising efficacy and overall tolerable toxicity profiles of combined modality treatment. There is significant interest in optimizing the treatment for patients with locally advanced cervical cancer beyond the standard of care-chemoradiation-which has been in place for the last 30 years. The majority of cervical cancer emerges after persistent infection with a high-risk subtype of the human papillomavirus, where viral oncoproteins lead to cellular changes and immortalization. As a result, immune tolerance can develop, resulting in cancer. Knowledge of the mechanism of human papillomavirus-related oncogenesis suggests that immune therapy or checkpoint blockade can reinvigorate an antitumor immune response. Current clinical trials are exploring the therapeutic potential of these approaches. Uterine cancers have been grouped into 4 molecular subclasses by their driver mutations, mutational burden, and copy-number alterations. Of these subgroups, the polymerase epsilon-mutated and microsatellite-unstable may represent up to 40% of endometrial cancers, and they have been shown to be immunogenic. Because of the inherent immunogenicity of these MSI-high tumors, combined immune modulation strategies, including chemotherapy, radiation, and immunotherapy and immune checkpoint inhibitor therapy, are being explored to improve treatment outcomes. In this review, we explore current immunomodulatory and multimodality therapeutic approaches in the treatment of cervical and uterine cancer through ongoing clinical trials investigating the combination of immunotherapy and radiation therapy.
引用
- Dyer BA, Feng CH, Eskander R, et al. Current Status of Clinical Trials for Cervical and Uterine Cancer Using Immunotherapy Combined With Radiation. Int J Radiat Oncol Biol Phys. 2020. PMID: 32942005. doi:10.1016/j.ijrobp.2020.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。